Compare Stocks → top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL) (From Traders Agency) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:CRTXNASDAQ:DNLINASDAQ:EDITNASDAQ:FATENASDAQ:RGNX Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRTXCortexyme$1.11+4.7%$1.18$1.78▼$40.66$33.47M1.4620,672 shs129,361 shsDNLIDenali Therapeutics$15.56-3.4%$19.15$15.45▼$33.31$2.30B1.331.07 million shs944,425 shsEDITEditas Medicine$5.35-2.0%$7.63$5.28▼$11.91$449M2.011.61 million shs1.91 million shsFATEFate Therapeutics$4.30-5.3%$6.84$1.63▼$8.83$516.73M1.662.08 million shs2.27 million shsRGNXREGENXBIO$16.04+0.9%$19.98$11.83▼$28.80$779.78M1.29443,297 shs425,390 shs7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRTXCortexyme+4.72%+11.00%-7.50%-16.54%-28.39%DNLIDenali Therapeutics-3.41%-7.49%-21.69%-9.53%-34.87%EDITEditas Medicine-2.01%-4.63%-27.31%-31.23%-30.52%FATEFate Therapeutics-5.29%-18.41%-37.41%-5.70%-28.69%RGNXREGENXBIO+0.88%-5.81%-25.71%+20.97%-15.22%Prepare for a recession unlike any other (Ad)These 42 powerful nations just launched the first-ever “Anti-Dollar Alliance”… And together, they plan to KILL the greenback and DETHRONE America once and for all. Leading the charge are the usual suspects: Russia, China, Iran, oil-soaked Saudi Arabia, and even our neighbor, Mexico. And because this alliance holds close to 70% of all US Dollars… Ditching their holdings could flood America with a tsunami of US Dollars… Triggering hyper-inflation and a Wall Street nosedive so deep, it VAPORIZES trillions in hard-earned retirement savings.GET THE FREE GUIDEMarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCRTXCortexymeN/AN/AN/AN/AN/AN/AN/AN/ADNLIDenali Therapeutics3.66 of 5 stars3.51.00.04.72.22.50.0EDITEditas Medicine3.5591 of 5 stars3.31.00.04.62.52.50.0FATEFate Therapeutics4.1452 of 5 stars4.01.00.04.71.92.50.6RGNXREGENXBIO4.6675 of 5 stars4.42.00.04.62.53.30.6Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCRTXCortexymeN/AN/AN/AN/ADNLIDenali Therapeutics3.00Buy$41.22164.92% UpsideEDITEditas Medicine2.56Moderate Buy$15.00180.37% UpsideFATEFate Therapeutics2.08Hold$6.7356.45% UpsideRGNXREGENXBIO2.83Moderate Buy$38.45139.74% UpsideCurrent Analyst RatingsLatest DNLI, FATE, RGNX, CRTX, and EDIT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/23/2024FATEFate TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$7.004/12/2024RGNXREGENXBIOStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$40.004/11/2024FATEFate TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingHold4/9/2024DNLIDenali TherapeuticsUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$70.00 ➝ $32.003/28/2024FATEFate TherapeuticsBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetUnderperform ➝ Underperform$2.00 ➝ $6.003/19/2024FATEFate TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral$7.003/11/2024RGNXREGENXBIOHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy$36.003/8/2024RGNXREGENXBIORoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeSector Perform ➝ Outperform$20.00 ➝ $35.003/7/2024RGNXREGENXBIOChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$52.003/7/2024RGNXREGENXBIOBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$45.00 ➝ $55.003/6/2024RGNXREGENXBIOLeerink PartnrsSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeMarket Perform ➝ Outperform(Data available from 4/25/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCRTXCortexymeN/AN/AN/AN/A$3.97 per shareN/ADNLIDenali Therapeutics$330.53M6.71N/AN/A$7.42 per share2.10EDITEditas Medicine$78.12M5.63N/AN/A$4.27 per share1.25FATEFate Therapeutics$63.53M7.70N/AN/A$3.74 per share1.15RGNXREGENXBIO$90.24M8.72N/AN/A$7.09 per share2.26Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCRTXCortexyme-$89.94M-$2.97N/AN/AN/AN/A-70.96%-63.53%N/ADNLIDenali Therapeutics-$145.22M-$1.08N/AN/AN/A-36.51%-13.50%-11.38%5/13/2024 (Estimated)EDITEditas Medicine-$153.22M-$2.05N/AN/AN/A-196.12%-42.95%-30.49%5/3/2024 (Estimated)FATEFate Therapeutics-$160.93M-$1.64N/AN/AN/A-253.30%-38.17%-28.42%5/1/2024 (Estimated)RGNXREGENXBIO-$263.49M-$6.03N/AN/AN/A-291.99%-68.18%-39.95%5/1/2024 (Estimated)Latest DNLI, FATE, RGNX, CRTX, and EDIT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails2/28/2024Q4 2023EDITEditas Medicine-$0.52-$0.23+$0.29-$0.23$4.84 million$60.00 million 2/27/2024Q4 2023DNLIDenali Therapeutics-$0.81-$0.86-$0.05-$0.86$3.38 millionN/A2/27/2024Q4 2023RGNXREGENXBIO-$1.27-$1.43-$0.16-$1.43$34.01 million$22.30 million 2/26/202412/31/2023FATEFate Therapeutics-$0.57-$0.45+$0.12-$0.45$0.85 million$1.68 million DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCRTXCortexymeN/AN/AN/AN/AN/ADNLIDenali TherapeuticsN/AN/AN/AN/AN/AEDITEditas MedicineN/AN/AN/AN/AN/AFATEFate TherapeuticsN/AN/AN/AN/AN/ARGNXREGENXBION/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCRTXCortexymeN/A9.929.92DNLIDenali TherapeuticsN/A13.6513.65EDITEditas MedicineN/A5.395.39FATEFate TherapeuticsN/A8.488.48RGNXREGENXBION/A2.572.57OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCRTXCortexyme63.18%DNLIDenali Therapeutics92.92%EDITEditas Medicine71.90%FATEFate Therapeutics97.54%RGNXREGENXBIO88.08%Insider OwnershipCompanyInsider OwnershipCRTXCortexyme27.90%DNLIDenali Therapeutics7.90%EDITEditas Medicine1.90%FATEFate Therapeutics5.04%RGNXREGENXBIO13.13%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableCRTXCortexyme5530.15 million21.74 millionNot OptionableDNLIDenali Therapeutics445142.54 million131.28 millionOptionableEDITEditas Medicine26582.24 million80.67 millionOptionableFATEFate Therapeutics181113.82 million108.08 millionOptionableRGNXREGENXBIO34449.04 million42.60 millionOptionableDNLI, FATE, RGNX, CRTX, and EDIT HeadlinesSourceHeadlineREGENXBIO to Participate in Chardan's 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summitprnewswire.com - April 24 at 7:05 AMREGENXBIO Inc. (NASDAQ:RGNX) Shares Sold by Raymond James & Associatesmarketbeat.com - April 23 at 4:04 AMMirae Asset Global Investments Co. Ltd. Reduces Holdings in REGENXBIO Inc. (NASDAQ:RGNX)marketbeat.com - April 21 at 4:35 AMKenneth T. Mills Sells 15,000 Shares of REGENXBIO Inc. (NASDAQ:RGNX) Stockinsidertrades.com - April 19 at 5:32 AMREGENXBIO (NASDAQ:RGNX) Stock Price Down 3.1% Following Insider Sellingamericanbankingnews.com - April 19 at 1:22 AMREGENXBIO (NASDAQ:RGNX) Shares Down 3.1% Following Insider Sellingmarketbeat.com - April 18 at 11:42 AMInsider Selling: REGENXBIO Inc. (NASDAQ:RGNX) CEO Sells 15,000 Shares of Stockmarketbeat.com - April 17 at 6:39 PMREGENXBIO Inc.'s (NASDAQ:RGNX) recent 7.9% pullback adds to one-year year losses, institutional owners may take drastic measuresfinance.yahoo.com - April 17 at 10:55 AMWhere Regenxbio Stands With Analystsmarkets.businessinsider.com - April 12 at 1:03 PMREGENXBIO (NASDAQ:RGNX) Earns "Buy" Rating from Stifel Nicolausmarketbeat.com - April 12 at 12:15 PMREGENXBIO Inc. (NASDAQ:RGNX) Receives Average Recommendation of "Moderate Buy" from Brokeragesmarketbeat.com - April 6 at 2:58 AMAssenagon Asset Management S.A. Invests $1.92 Million in REGENXBIO Inc. (NASDAQ:RGNX)marketbeat.com - April 5 at 4:29 AMRegenxbio Stock (NASDAQ:RGNX), Quotes and News Summarybenzinga.com - March 31 at 10:27 PMREGENXBIO (NASDAQ:RGNX) Stock Price Down 2%marketbeat.com - March 28 at 4:33 PMREGENXBIO Sees Positive Results For Macular Degeneration Therapyfinance.yahoo.com - March 28 at 1:40 PMREGENXBIO Announces Lancet Publication of Phase I/IIa Study Evaluating ABBV-RGX-314 as a One-Time Gene Therapy for Wet AMDprnewswire.com - March 28 at 7:05 AMREGENXBIO to Participate in Cantor Fitzgerald's Virtual DMD and Other Dystrophy Daysfinance.yahoo.com - March 27 at 5:33 PMREGENXBIO Inc. (NASDAQ:RGNX) CEO Sells $327,900.00 in Stockinsidertrades.com - March 19 at 5:00 AMRegenxbio Inc (RGNX) President and CEO Kenneth Mills Sells 15,000 Sharesfinance.yahoo.com - March 18 at 9:18 PMREGENXBIO Inc. (NASDAQ:RGNX) Insider Steve Pakola Sells 12,878 Sharesinsidertrades.com - March 17 at 7:41 AMRockville biotech raises $140M following layoffs, program cutsbizjournals.com - March 12 at 8:13 PMRegenxbio: DMD Program Lends Additional Credibility To NAV Technology Platformseekingalpha.com - March 11 at 2:02 PMRegenxbio initiated with bullish view at H.C. Wainwright, here's whyrealmoney.thestreet.com - March 11 at 2:02 PMREGENXBIO to Participate in Upcoming Investor Conferencesprnewswire.com - March 11 at 7:05 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsCortexymeNASDAQ:CRTXCortexyme, Inc., a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer's and other degenerative diseases. Its lead drug candidate is atuzaginstat (COR388), an orally administered brain-penetrating small molecule gingipain inhibitor, which is in Phase II/III clinical trial for use in patients with mild to moderate Alzheimer's disease, as well as for the treatment of oral squamous cell carcinoma, periodontitis, and coronavirus infection. The company was incorporated in 2012 and is headquartered in South San Francisco, California.Denali TherapeuticsNASDAQ:DNLIDenali Therapeutics Inc., a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2. Its brain-penetrant small molecule programs comprise BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; SAR443820/DNL788 RIPK1 inhibitor program for CNS disease; DNL343 eIF2B Activator program for amyotrophic lateral sclerosis; and SAR443122/DNL758 RIPK1 inhibitor program for peripheral inflammatory diseases. It also provides early stage program include TAK-594/DNL593 program for FTD-GRN; DNL126 program for MPS IIIA, a Sanfilippo Syndrome A; DNL622 for MPS I which is Hurler syndrome; Antibody Transport Vehicle Amyloid beta program; Oligonucleotide Transport Vehicle platform, a novel class of biotherapeutics to address the root cause of diseases through modulation of gene expression; and other TV-enabled discovery programs. The company has collaboration agreements with Biogen MA Inc. and Biogen International GmbH; Genzyme Corporation; Takeda Pharmaceutical Company Limited; F-star Gamma Limited, F-star Biotechnologische Forschungs-und Entwicklungsges m.b.H, and F-star Biotechnology Limited; and Genentech, Inc. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.Editas MedicineNASDAQ:EDITEditas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.Fate TherapeuticsNASDAQ:FATEFate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.REGENXBIONASDAQ:RGNXREGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy. It also develops RGX-121 for the treatment of mucopolysaccharidosis type II that is in Phase III clinical trial; RGX-111 for treating mucopolysaccharidosis type I; RGX-181 for the treatment of late infantile neuronal ceroid lipofuscinosis type II; and RGX-381 to treat the ocular manifestations of CLN2 disease. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.